## 1 Introduction
\begin{table}
\begin{tabular}{c c c c c c c} \hline \hline
**Drug 1** & **Dose** & **Imax** & **Iin,max** & **f\({}_{\text{U}}\) 2** & **i\({}_{\text{in,max,u}}\)** & **IC\({}_{\text{50}}\)** & **R 4** \\  & **(mg)** & **(\(\mu\)M) 2** & **(\(\mu\)M) 2** & **(\(\mu\)M) 2** & **(\(\mu\)M) 2** & **(\(\mu\)M) 3** & **R 4** \\ \hline Bendrofflumethiazide [5] & 10 [12] & 0.2 [12] & 1.68 & 0.06 [13] & 0.101 & 77 & 1.00 \\ Bosentan & 125 [14] & 4.2 [14] & 18.2 & 0.02 [15] & 0.365 & 24 [16] & 1.02 \\ Budesonide [5] & 0.8 [17] & 0.0026 [17] & 0.12 & 0.13 [13] & 0.015 & 320 & 1.00 \\ Bulevirtide (Myrcludex B) & 2 [8] & 0.04 [8] & 0.07 & 0.85 [18] & 0.056 & 0.053 [19] & 2.06 \\ Candesartan [5] & 32 [20] & 0.75 [20] & 5.26 & 0.01 [13] & 0.053 & 339 & 1.00 \\ Cyclosporin A & 700 [21] & 0.45 [21] & 36.6 & 0.12 [21] & 4.39 & 1 [22] & 5.39 \\ Cyclosporin A & 200 [23] & 1.8 [23] & 12.2 & 0.1 [23] & 1.22 & 1 [22] & 2.22 \\ Diliazem [5] & 180 [21] & 0.29 [21] & 27.3 & 0.3 [21] & 8.17 & 871 & 1.01 \\ Diliazem [5] & 120 [23] & 0.36 [23] & 18.3 & 0.22 [23] & 4.04 & 871 & 1.00 \\ Doxazosin [5] & 8 [24] & 0.06 [24] & 1.16 & 0.02 [24] & 0.023 & 51 & 1.00 \\ Efavirenz & 600 [25] & 11.6 [25] & 129.7 & 0.01 [13] & 1.3 & 43 [26] & 1.03 \\ Ezetimibe [5] & 10 [24] & 0.01 [24] & 1.53 & 0.1 [24] & 0.153 & 36 & 1.00 \\ Fenofibrate [5] & 300 [23] & 23.8 [23] & 75.5 & 0.01 [13] & 0.755 & 188 & 1.00 \\ Flutamide [5] & 250 [24] & 0.4 [24] & 56.6 & 0.06 [24] & 3.4 & 164 & 1.02 \\ Furesomide & 80 [27] & 6.7 [27] & 21.7 & 0.01 [13] & 0.217 & 15 [22] & 1.01 \\ Gemfirozil [5] & 600 [23] & 60.9 [23] & 209.8 & 0.0065 [23] & 1.36 & 23 & 1.06 \\ Glyburide [5] & 5 [24] & 0.2 [24] & 0.83 & 0.02 [24] & 0.017 & 11 & 1.00 \\ Indomethacinic [5] & 50 [28] & 7.7 [28] & 16.4 & 0.03 [13] & 0.492 & 251 & 1.00 \\ Irbesartan [5] & 300 [24] & 7.7 [24] & 51.2 & 0.1 [24] & 5.12 & 17 & 1.30 \\ Ketokonazole & 200 [24] & 8.5 [24] & 31.9 & 0.01 [24] & 0.319 & 264 [22] & 1.00 \\ Ketokonazole & 200 [21] & 6.6 [21] & 30.0 & 0.01 [21] & 0.3 & 264 [22] & 1.00 \\ Ketokonazole & 200 [23] & 3.2 [23] & 26.6 & 0.01 [23] & 0.266 & 264 [22] & 1.00 \\ Ketoprofen [5] & 100 [29] & 39.7 [29] & 64.2 & 0.03 [13] & 1.92 & 467 & 1.00 \\ Lapatinib [5] & 1250 [23] & 4.2 [23] & 137.8 & 0.01 [23] & 1.38 & 415 & 1.00 \\ Losartan [5] & 50 [24] & 0.5 [24] & 7.84 & 0.01 [24] & 0.078 & 105 & 1.00 \\ Methylprednisolone [5] & 1000 [21] & 26.5 [21] & 192.4 & 0.22 [21] & 42.3 & 346 & 1.12 \\ Nategljndic [5] & 60 [30] & 15.5 [30] & 27.3 & 0.02 [13] & 0.546 & 290 & 1.00 \\ Nefazodone [5] & 200 [31] & 4.4 [31] & 30.8 & 0.01 [13] & 0.308 & 183 & 1.00 \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Clinical parameters and extrapolations for NTCP inhibitor drugs. Notably, in 2012, NTCP/_SLC10A1_ has been identified as a cellular receptor for viral entry of the human hepatitis B virus (HBV) and its satellite hepatitis D virus (HDV) [41; 42]. Susceptibility to HBV infection majorly depends on NTCP expression and overlaps with species and cell type-specific expression of NTCP [43]. NTCP mediates viral entry of HBV/HDV by its specific interaction with the pre-S1 domain of HBV large envelope protein, which is essential for infection of target cells. The amino acids 84-87 and 157-165 of NTCP have been elucidated to be important for HBV binding and infection [42]. While the crystal structures of bacterial homologs of the SLC10 family have been known for some time [44; 45], the structure of mammalian NTCP has only recently been reported by three independent groups providing further insight into HBV recognition and entry [46; 47; 48]. Based on the various ways in which NTCP acts as an endogenous and pharmacological target as well as a potential susceptibility factor for HBV/HDV infection, it is clinically important to systematically elucidate the inter-individual variability in expression and function of NTCP. Subsequently, factors that may significantly explain inter-individual variability are important to enable in vivo prediction of NTCP function.